This approach not only enhances the appeal of the products but also aligns with consumers broader goals of self-improvement and emotional well-being
Safety and tolerability were predefined as the primary endpoint and assessed by treatment-emergent adverse events (TEAEs)
Peer-Reviewed Study Retatrutide: Triple Hormone Receptor Agonism and Effects on Body Weight and Metabolic Function Introduction to Retatrutide Retatrutide is a novel synthetic peptide designed as a triple agonist targeting glucagon, GLP-1 (glucagon-like peptide-1), and GIP (glucose-dependent insulinotropic polypeptide) receptors
As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Associations Standards of Medical Care in Diabetes (248, 249)
Greene CRL, Blackbourn LAK, McGurnaghan SJ, Mercer SW, Smith DJ, Wild SH, et al